These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18574040)

  • 21. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.
    Rüfer A; Brodmann D; Gregor M; Kremer Hovinga JA; Lämmle B; Wuillemin WA
    Swiss Med Wkly; 2007 Sep; 137(37-38):518-24. PubMed ID: 17990141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
    Galbusera M; Bresin E; Noris M; Gastoldi S; Belotti D; Capoferri C; Daina E; Perseghin P; Scheiflinger F; Fakhouri F; Grünfeld JP; Pogliani E; Remuzzi G
    Blood; 2005 Aug; 106(3):925-8. PubMed ID: 15827129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
    Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R; Machin S; Scully M; Purdy G; Mackie I
    Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.
    Loirat C; Girma JP; Desconclois C; Coppo P; Veyradier A
    Pediatr Nephrol; 2009 Jan; 24(1):19-29. PubMed ID: 18574602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease].
    Coppo P; Veyradier A; Monge M;
    Presse Med; 2006 Dec; 35(12 Pt 2):1876-86. PubMed ID: 17159713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge.
    Kwaan HC
    Semin Thromb Hemost; 2005 Dec; 31(6):615-24. PubMed ID: 16388412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Expert Opin Pharmacother; 2007 Mar; 8(4):437-44. PubMed ID: 17309338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
    Zheng XL
    Annu Rev Med; 2015; 66():211-25. PubMed ID: 25587650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S88-91. PubMed ID: 22407740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of thrombotic thrombocytopenic purpura].
    Ueda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):2076-86. PubMed ID: 25297774
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
    Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
    Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
    Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
    Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.
    Hagel S; Jantsch J; Budde U; Kalden JR; Eckardt KU; Veelken R
    Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551
    [No Abstract]   [Full Text] [Related]  

  • 40. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
    Peyvandi F; Mannucci PM; Valsecchi C; Pontiggia S; Farina C; Retzios AD
    Am J Hematol; 2013 Oct; 88(10):895-8. PubMed ID: 23813910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.